Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?

被引:35
作者
Holle, JU
Hellmich, B
Backes, M
Gross, WL
Csernok, E
机构
[1] Rheumaklin Bad Bramstedt, D-24576 Bad Bramstedt, Germany
[2] Dept Rheumatol, Lubeck, Germany
关键词
D O I
10.1136/ard.2005.035279
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Previous studies have shown considerable variation in diagnostic performance of enzyme linked immunosorbent assays (ELISAs) for measuring antineutrophil cytoplasmic antibodies (ANCA) specific for proteinase 3 (PR3) and myeloperoxidase (MPO). Objective: To analyse the performance characteristics of different commercially available direct ANCA ELISA kits. Methods: ELISA kits for detecting PR3-ANCA and MPO-ANCA from 11 manufacturers were evaluated. Serum samples were taken from patients with Wegener's granulomatosis (15), microscopic polyangiitis (15), other vasculitides (10), and controls (40). Results were compared with data obtained by indirect immunofluorescence (IFT). The diagnostic performance of the tests was analysed and compared by receiver operating characteristic (ROC) curve analysis. Results: Applying the manufacturers' cut off resulted in great variation in sensitivity of the commercial PR3ANCA kits for diagnosing Wegener's granulomatosis (ranging from 13.3% to 66.7%), and of the MPO-ANCA kits for diagnosing microscopic polyangiitis (ranging from 26.7% to 66.7%). Specificities were relatively constant (from 96.0% to 100%). IFT was superior to all ELISAs (C-ANCA for Wegener's granulomatosis: sensitivity 73.3%, specificity 98%; P-ANCA for microscopic polyangiitis: sensitivity 86.7%, specificity 98%). The sensitivities of PR3-ANCA and MPO-ANCA ELISA kits were increased by lowering the cut off values. This reduced specificity but increased overall diagnostic performance. Conclusions: The low sensitivity of some commercial kits reflects the high cut off levels recommended rather than methodological problems with the assays. Comparative analyses using sera from well characterised patients may help identify optimum cut off levels of commercial ANCA ELISA tests, resulting in better comparability of results among assays from different manufacturers.
引用
收藏
页码:1773 / 1779
页数:7
相关论文
共 15 条
[1]  
Boomsma MM, 2000, ARTHRITIS RHEUM-US, V43, P2025, DOI 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO
[2]  
2-O
[3]   Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study [J].
Csernok, E ;
Holle, J ;
Hellmich, B ;
Willem, J ;
Tervaert, C ;
Kallenberg, CGM ;
Limburg, PC ;
Niles, J ;
Pan, GL ;
Specks, U ;
Westman, K ;
Wieslander, J ;
De Groot, K ;
Gross, WL .
RHEUMATOLOGY, 2004, 43 (02) :174-180
[4]   A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis [J].
Csernok, E ;
Ahlquist, D ;
Ullrich, S ;
Gross, WL .
RHEUMATOLOGY, 2002, 41 (11) :1313-1317
[5]   Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis [J].
Hagen, EC ;
Daha, MR ;
Hermans, J ;
Andrassy, K ;
Csernok, E ;
Gaskin, G ;
Lesavre, P ;
Lüdemann, J ;
Rasmussen, N ;
Sinico, RA ;
Wiik, A ;
van der Woude, FJ .
KIDNEY INTERNATIONAL, 1998, 53 (03) :743-753
[6]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[7]   NOMENCLATURE OF SYSTEMIC VASCULITIDES - PROPOSAL OF AN INTERNATIONAL CONSENSUS CONFERENCE [J].
JENNETTE, JC ;
FALK, RJ ;
ANDRASSY, K ;
BACON, PA ;
CHURG, J ;
GROSS, WL ;
HAGEN, EC ;
HOFFMAN, GS ;
HUNDER, GG ;
KALLENBERG, CGM ;
MCCLUSKEY, RT ;
SINICO, RA ;
REES, AJ ;
VANES, LA ;
WALDHERR, R ;
WIIK, A .
ARTHRITIS AND RHEUMATISM, 1994, 37 (02) :187-192
[8]   THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY 1990 CRITERIA FOR THE CLASSIFICATION OF WEGENER GRANULOMATOSIS [J].
LEAVITT, RY ;
FAUCI, AS ;
BLOCH, DA ;
MICHEL, BA ;
HUNDER, GG ;
AREND, WP ;
CALABRESE, LH ;
FRIES, JF ;
LIE, JT ;
LIGHTFOOT, RW ;
MASI, AT ;
MCSHANE, DJ ;
MILLS, JA ;
STEVENS, MB ;
WALLACE, SL ;
ZVAIFLER, NJ .
ARTHRITIS AND RHEUMATISM, 1990, 33 (08) :1101-1107
[9]  
Lim LCL, 1999, AM J CLIN PATHOL, V111, P363
[10]  
LUQMANI RA, 1994, Q J MED, V87, P671